BACILIERI, MAGDALENA
 Distribuzione geografica
Continente #
NA - Nord America 1.372
AS - Asia 552
EU - Europa 287
AF - Africa 142
SA - Sud America 123
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 5
Totale 2.502
Nazione #
US - Stati Uniti d'America 1.313
SG - Singapore 232
CN - Cina 116
BR - Brasile 73
HK - Hong Kong 47
VN - Vietnam 45
DE - Germania 41
FI - Finlandia 33
IT - Italia 24
NL - Olanda 22
FR - Francia 20
UA - Ucraina 14
MX - Messico 12
EC - Ecuador 11
SE - Svezia 11
IE - Irlanda 10
MZ - Mozambico 10
RU - Federazione Russa 10
AR - Argentina 9
GB - Regno Unito 9
ZA - Sudafrica 9
TR - Turchia 8
AM - Armenia 7
KZ - Kazakistan 7
LV - Lettonia 7
UY - Uruguay 7
VE - Venezuela 7
AE - Emirati Arabi Uniti 6
AT - Austria 6
BY - Bielorussia 6
CR - Costa Rica 6
DZ - Algeria 6
EE - Estonia 6
GA - Gabon 6
JM - Giamaica 6
MR - Mauritania 6
PL - Polonia 6
TN - Tunisia 6
UG - Uganda 6
AU - Australia 5
BG - Bulgaria 5
DJ - Gibuti 5
GH - Ghana 5
GT - Guatemala 5
IR - Iran 5
JO - Giordania 5
JP - Giappone 5
LU - Lussemburgo 5
SO - Somalia 5
TJ - Tagikistan 5
UZ - Uzbekistan 5
BF - Burkina Faso 4
BJ - Benin 4
BW - Botswana 4
CG - Congo 4
CM - Camerun 4
CO - Colombia 4
CV - Capo Verde 4
CY - Cipro 4
DK - Danimarca 4
ES - Italia 4
HN - Honduras 4
ID - Indonesia 4
IN - India 4
IS - Islanda 4
KR - Corea 4
LC - Santa Lucia 4
LY - Libia 4
ML - Mali 4
MU - Mauritius 4
NC - Nuova Caledonia 4
PF - Polinesia Francese 4
PY - Paraguay 4
RO - Romania 4
SI - Slovenia 4
SK - Slovacchia (Repubblica Slovacca) 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
AF - Afghanistan, Repubblica islamica di 3
AZ - Azerbaigian 3
BD - Bangladesh 3
BE - Belgio 3
BZ - Belize 3
CD - Congo 3
CL - Cile 3
CW - ???statistics.table.value.countryCode.CW??? 3
EG - Egitto 3
GM - Gambi 3
GR - Grecia 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
MA - Marocco 3
ME - Montenegro 3
MG - Madagascar 3
MN - Mongolia 3
PG - Papua Nuova Guinea 3
PK - Pakistan 3
RS - Serbia 3
YT - Mayotte 3
ZM - Zambia 3
Totale 2.420
Città #
Fairfield 197
Singapore 155
Ashburn 126
Woodbridge 109
Chandler 86
Houston 85
Santa Clara 84
Cambridge 74
Jacksonville 67
Wilmington 66
Seattle 58
Hong Kong 45
Princeton 33
Ann Arbor 30
Boardman 25
Des Moines 23
Beijing 22
San Diego 19
Dong Ket 13
Munich 13
Ho Chi Minh City 12
Helsinki 11
Columbus 9
Los Angeles 9
Nanjing 9
Dublin 8
Hanoi 8
Maputo 8
Buffalo 6
Falls Church 6
Johannesburg 6
Kampala 6
Montevideo 6
Nouakchott 6
Riga 6
Tallinn 6
Tianjin 6
Yerevan 6
Amman 5
Brooklyn 5
Council Bluffs 5
Dushanbe 5
Libreville 5
Medford 5
Padova 5
San José 5
São Paulo 5
Tashkent 5
Tokyo 5
Turku 5
Vienna 5
Accra 4
Atlanta 4
Bamako 4
Castries 4
Frankfurt am Main 4
Gaborone 4
Kingston 4
Ljubljana 4
Mexico City 4
Minsk 4
Nanchang 4
Noumea 4
Ouagadougou 4
Papeete 4
Praia 4
Quito 4
Shenyang 4
Treviso 4
Yenibosna 4
Baku 3
Boston 3
Chicago 3
Cotonou 3
Denver 3
Djibouti 3
Guatemala City 3
Guayaquil 3
Hargeisa 3
Hebei 3
Jinan 3
Kinshasa 3
Lusaka 3
Luxembourg 3
New York 3
Nicosia 3
Port Moresby 3
Reykjavik 3
Salvador 3
Sofia 3
São Gonçalo 3
Tehran 3
Tripoli 3
Tunis 3
Ulan Bator 3
Vientiane 3
Warsaw 3
Willemstad 3
Abu Dhabi 2
Almaty 2
Totale 1.693
Nome #
Combining ligand-based and structure-based drug design in the virtual screening arena 195
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: a complete structure -activity profile. 184
Tandem 3D-QSARs approach as a valuable tool to predict binding affinity data: Design of new Gly/NMDA receptor antagonists as a key study 182
G protein-coupled receptors as challenging druggable targets: insights from in silico studies 180
A Novel Generalized 3D-QSAR Model of Camptothecin Analogs 179
Fit-For-Purpose PD-L1 Biomarker Testing for Patient Selection in Immuno-Oncology: Guidelines for Clinical Laboratories from the Canadian Association of Pathologists-Association Canadienne des Pathologistes (CAP-ACP) 175
Ligand-based homology modeling as attractive tool to inspect GPCR structural plasticity 158
Revisiting a Receptor-Based Pharmacophore Hypothesis for Human A2AAdenosine Receptor Antagonists 152
Autocorrelation of Molecular Electrostatic Potential Surface Properties Combined with Partial Least Squares Analysis as New Strategy for the Prediction of the Activity of Human A3 Adenosine Receptor Antagonists. 146
Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo-pyrimidine antagonists binding site of the human adenosine A(2A) receptor 137
Novel strategies for the design of new potent and selective human A3 receptor antagonists: an update 134
Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites 129
Prediction of the acqueous solvation free energy of organic compounds by using autocorrelation of molecular electrostatic potential surface properties combined with response surface analysis 128
The application of a 3D-QSAR (autoMEP/PLS) approach as an efficient pharmacodynamic-driven filtering method for small-sized virtual library: Application to a lead optimization of a human A(3) adenosine receptor antagonist 118
Combining selectivity and affinity predictions using an integrated support vector machine (SVM) approach: a novel tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites 115
Inhibitory effects of glycosaminoglycans on basal and stimulated transforming growth factor-beta 1 expression in mesangial cells: biochemical and structural considerations 106
Response Surface Analysis as aternative 3D-QSAR tool: human A3 adenosine receptor antagonists as a key study. 88
Totale 2.506
Categoria #
all - tutte 8.276
article - articoli 8.276
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.552


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021128 0 0 0 0 0 31 0 9 33 13 25 17
2021/2022257 12 37 32 20 4 11 18 28 5 8 33 49
2022/2023197 36 7 0 18 33 55 0 14 25 0 7 2
2023/202486 4 14 16 9 9 1 9 7 2 1 7 7
2024/2025456 0 75 18 27 87 16 12 30 10 15 69 97
2025/2026848 43 96 216 248 205 40 0 0 0 0 0 0
Totale 2.506